| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xavier Adhoute, Edouard Larrey, Rodolphe Anty, Patrick Chevallier, Guillaume Penaranda, Albert Tran, Jean-Pierre Bronowicki, Jean-Luc Raoul, Paul Castellani, Hervé Perrier, Olivier Bayle, Olivier Monnet, Bernard Pol and Marc Bourliere |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xavier Adhoute, N/A, Doctor, Department of Gastroenterology and Hepatology, Hôpital Saint-Joseph, 26 Bd de Louvain, Marseille 13008, France. xvadhoute@gmail.com |
| Key Words |
Hepatocellular carcinoma; Transarterial chemoembolization; Pre-TACE-predict; Six-and-twelve; Barcelona Clinic Liver Cancer; Prognosis |
| Core Tip |
Management of hepatocellular carcinoma (HCC) has significantly changed over the past few years. The introduction of new systemic therapies, including immune checkpoint inhibitors has improved survival, especially in advanced stages HCC patients. Careful selection of patients prior to transarterial chemoembolization (TACE) is furthermore essential. Up-to-seven criteria have been proposed for subclassification of intermediate stages. More recently, two models (6 and 12; pre-TACE-predict) have been developed to improve patient stratification and refine prognosis, overcoming based-point scores limitations. In this retrospective multi-center French study, we evaluated and compared these two new models both to validate their prognostic value and applicability in clinical current practice. |
| Publish Date |
2021-06-11 09:22 |
| Citation |
Adhoute X, Larrey E, Anty R, Chevallier P, Penaranda G, Tran A, Bronowicki JP, Raoul JL, Castellani P, Perrier H, Bayle O, Monnet O, Pol B, Bourliere M. Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results. World J Clin Cases 2021; 9(18): 4559-4572 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i18/4559.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i18.4559 |
